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Protein modification by O-linked b-N-acetylglucos-
amine (O-GlcNAc) is a critical cell signaling modality,
but identifying signal-specific O-GlcNAcylation
events remains a significant experimental challenge.
Here, we describe a method for visualizing and
analyzing organelle- and stimulus-specific O-GlcNA-
cylated proteins and use it to identify the mitochon-
drial voltage-dependent anion channel 2 (VDAC2)
as an O-GlcNAc substrate. VDAC2/ cells resist
the mitochondrial dysfunction and apoptosis caused
by global O-GlcNAc perturbation, demonstrating
a functional connection between O-GlcNAc signaling
and mitochondrial physiology through VDAC2. More
broadly, our method will enable the discovery of
signal-specific O-GlcNAcylation events in a wide
array of experimental contexts.INTRODUCTION
Modification of intracellular proteins by O-linked b-N-acetylglu-
cosamine (O-GlcNAcylation) has emerged recently as a ubi-
quitous cell signaling modality in a broad range of organisms,
influencing such core cell biological processes as transcription,
nutrient sensing, and cell-cycle progression (Hanover et al.,
2010; Hart et al., 2011). Analogous to phosphorylation,
O-GlcNAcylation is a dynamic, rapidly cycling posttranslational
modification that modulates substrate proteins’ location, func-
tion, or stability in response to physiological signals (Hanover
et al., 2010; Hart et al., 2011). Accordingly, it is of great interest
to identify which substrate proteins are O-GlcNAcylated in
response to a given biological cue. However, this goal poses a
substantial experimental challenge, in part because rare,
signal-dependent changes in O-linked b-N-acetylglucosamine546 Cell Reports 5, 546–552, October 31, 2013 ª2013 The Authors(O-GlcNAc) are difficult to detect amidst the large number of
abundant, constitutively, and multiply glycosylated ‘‘back-
ground’’ proteins (e.g., nucleoporins). Although chemical (Wells
et al., 2002), chemoenzymatic (Khidekel et al., 2003), lectin-
(Vosseller et al., 2006), and antibody- (Teo et al., 2010) based
methods for identifying O-GlcNAcylated proteins have been
described, these approaches all rely on affinity purification to
enrich substrates and are therefore inherently biased toward
abundant, unchanging ‘‘background’’ O-GlcNAc, at the expense
of the comparatively rare, substoichiometric, signal-dependent
changes in O-GlcNAc. Therefore, new, complementary methods
are needed for identifying functionally relevant changes in pro-
tein O-GlcNAcylation.
We have previously described a strategy for identifying
O-GlcNAcylated proteins in living mammalian cells using the un-
natural azide-functionalized sugar N-azidoacetylgalactosamine
(GalNAz) as a metabolic label (Boyce et al., 2011). Briefly, we
showed that GalNAz is converted by endogenous metabolic en-
zymes to the nucleotide-sugar UDP-GalNAz and then epimer-
ized to UDP-N-azidoacetylglucosamine (GlcNAz), the azido
analog of natural UDP-GlcNAc (Boyce et al., 2011; Vocadlo
et al., 2003). O-GlcNAc transferase (OGT) accepts UDP-GlcNAz
as a nucleotide-sugar donor, resulting in the installation of
‘‘O-GlcNAz’’ on native OGT substrates (Figure 1A) (Boyce
et al., 2011; Vocadlo et al., 2003). The resulting azide-functional-
ized (‘‘O-GlcNAzylated’’) proteins can then be chemically tagged
using any of several classes of azide-reactive probes (Figure 1A)
(Boyce and Bertozzi, 2011; Boyce et al., 2011). Importantly, this
strategy allows for selective labeling of new O-GlcNAc moieties
(i.e., those formed after GalNAz is added to cells), affording time-
resolution control not provided by other methods of O-GlcNAc
detection. We have previously used affinity probes to purify
bulk endogenous, O-GlcNAzylated proteins, revealing numerous
knownO-GlcNAc substrates and demonstrating that GalNAz is a
faithful and robust metabolic reporter of cellular O-GlcNAc
(Boyce et al., 2011). Here, we build upon our GalNAz meta-
bolic-labeling strategy to create a proteomics platform for
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Figure 1. Glyco-DIGE System
(A) Endogenous O-GlcNAcylated proteins can be metabolically labeled by the conversion of GalNAz to UDP-GlcNAz, as described (Boyce et al., 2011). Such
O-GlcNAzylated substrates can then be detected by chemical tagging with one of several azide-reactive probes. CuAAC is depicted here. The yellow stars
represent a useful chemical moiety on the probe molecule, such as a fluorophore or affinity handle.
(B) Glyco-DIGE workflow is illustrated. First, protein extracts are made from two populations of cells (e.g., control and drug treated) that have been treated with
GalNAz to metabolically label O-GlcNAc substrates with an azidoglycan (O-GlcNAz), as described (Boyce et al., 2011). The two protein samples are then labeled
separately with azide-reactive Cy3- and Cy5-based dyes, mixed, and analyzed by 2D gel (horizontal dimension is for IEF; vertical dimension is for SDS-PAGE).
When the gel is scanned, protein spots unchanged between samples appear as dual-color overlap (yellow), whereas proteins unique to one sample appear as
single color spots (green indicates Cy3; red indicates Cy5), thereby permitting ready detection of sample-specific changes in O-GlcNAcylated proteins.
(C) Glyco-DIGE alkyne-functionalized fluorescent probes are shown.
(D) Glyco-DIGE probes specifically label azidosugar-tagged mammalian proteins. Jurkat cells were metabolically labeled with 100 mM peracetylated GalNAz
(Ac4GalNAz) or vehicle only for 24 hr. Whole-cell lysates were reacted with 1 or 2 via CuAAC and analyzed by standard SDS-PAGE and fluorescence scanning.
(E) 1 and 2 do not differentially affect protein migration in 2D gels. Jurkat cells were metabolically labeled with 100 mM Ac4GalNAz for 24 hr. Then, mitochondria
were purified and extracted into lysis buffer. Half the sample was labeled with 1 and half with 2, and labeled samples were analyzed by glyco-DIGE. 1 is indicated
in green, 2 in red, and 1+2 overlap in yellow.
See also Figure S8.
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identifying compartment- or stimulus-specific changes in
O-GlcNAcylated proteins across different samples, circumvent-
ing major, inherent disadvantages of affinity-based approaches.
Furthermore, we use our approach to identify a mitochondrial
glycoprotein and demonstrate its functional link to O-GlcNAc
signaling.
RESULTS
Glyco-DIGE Permits Simultaneous Detection and
Analysis of Hundreds of O-GlcNAcylated Proteins
To analyze sample-specific changes in O-GlcNAcylated pro-
teins, we turned to difference gel electrophoresis (DIGE) (Minden
et al., 2009). In traditional DIGE experiments, each of two protein
samples (e.g., from control versus stimulated cells) is covalently
labeled with a protein-nonspecific, cyanine 3 (Cy3)- or cyanine 5
(Cy5)-based fluorophore (Minden et al., 2009). Then, the samples
are mixed and analyzed by conventional 2D electrophoresis (iso-
electric focusing [IEF] followed by SDS-PAGE). When these 2D
gels are imaged for Cy3 and Cy5, proteins that are unchanged
between the two samples show perfect overlap of Cy3 and
Cy5 fluorescence, whereas the rare proteins that are different
between the two samples are visualized as Cy3-only or Cy5-
only signal. These sample-specific proteins of interest can be
excised from the gel and identified by mass spectrometry.
We envisioned that DIGE methods could be adapted to
analyze glycoproteins, including O-GlcNAcylated substrates
tagged via our GalNAz label and appropriate azide-reactive
Cy3 and Cy5 derivatives, permitting us to visualize and identify
sample-specific changes in O-GlcNAcylated proteins (Figures
1A and 1B). Furthermore, we hypothesized that this ‘‘glyco-
DIGE’’ platform would permit the visualization of rare, sample-
dependent changes in O-GlcNAcylated proteins, even in
experiments where abundant, unchanging background
O-GlcNAc is present elsewhere on the same 2D gel. Importantly,
such a glyco-DIGE approach could detect any alteration in an
O-GlcNAcylated protein that affected its mobility on a 2D gel,
including de novo (de)glycosylation and other changes (e.g.,
cleavage, ubiquitination), providing broad information on the
role of O-GlcNAcylated proteins in dynamic cell signaling.
To test the utility of a glyco-DIGE approach, we synthesized
alkyne-functionalized Cy3 (1) and Cy5 (2) (Figure 1C). As ex-
pected, 1 and 2 reacted specifically with O-GlcNAcylated pro-
teins from Jurkat cells metabolically labeled with GalNAz via
the well-characterized, bioorthogonal copper-catalyzed azide-
alkyne cycloaddition (CuAAC) reaction (Nwe and Brechbiel,
2009) (Figure 1D). Importantly, whereas hundreds of 1- and 2-
labeled protein spots could be separated and visualized effi-
ciently on the same glyco-DIGE gel, labeling by 1 or 2 did not
differentially affect the migration of proteins in a glyco-DIGE
experiment (Figure 1E). We concluded that glyco-DIGE can label
and compare large numbers of O-GlcNAcylated proteins across
different mammalian samples.
Glyco-DIGE Identifies VDAC2 as a Mitochondrial O-
GlcNAc Substrate
We next asked whether glyco-DIGE could detect sample-
specific differences in O-GlcNAcylated proteins. As a proof of548 Cell Reports 5, 546–552, October 31, 2013 ª2013 The Authorsprinciple experiment, we examined differences in protein glyco-
sylation between mitochondria and cytosol. Although O-GlcNAc
is a well-known sentinel of cellular glucose levels (Hanover et al.,
2010; Hart et al., 2011) and regulates both metabolic (Dentin
et al., 2008; Yang et al., 2008) and mitochondrial (Hu et al.,
2009; Wang and Schwarz, 2009) pathways, the mitochondrial
glycoproteome has not been analyzed systematically. We used
glyco-DIGE to compare O-GlcNAcylated proteins from mito-
chondrial and cytosolic extracts (Figure S1) (Frezza et al.,
2007) of the same human cell line. As expected, we detected
numerous differences in the respective glycoproteomes of these
two compartments (Figure 2A). Across many experiments and
multiple cell types, we noticed one set of especially prominent
mitochondrial O-GlcNAcylated protein spots (Figure 2A, arrows).
Using fluorescence as a guide, we excised the corresponding
spots from preparative gels and identified the voltage-depen-
dent anion channel 2 (VDAC2) protein as the major component
(Figure S2).
VDAC2 is a member of a family of multipass channel proteins
residing in the mitochondrial outer membrane, with important
roles in organelle metabolite flux, nutrient metabolism, and
apoptotic signaling (Cheng et al., 2003; Ren et al., 2009;
Shoshan-Barmatz et al., 2010). Although some work has sug-
gested that VDAC family proteins might be glycosylated (Jones
et al., 2008), VDAC2 had not been described or validated as a
specific O-GlcNAc substrate. We performed two experiments
to confirm our glyco-DIGE results with VDAC2. First, we
compared mitochondrial extracts from wild-type and VDAC2/
mouse embryonic fibroblasts (MEFs) (Cheng et al., 2003) in a
glyco-DIGE experiment (Figure 2B). As expected, we found
that spots corresponding to the ones identified in human cells
were present in wild-type MEF mitochondrial samples but
absent from the VDAC2/ samples, indicating that these spots
are VDAC2 (Figure 2B). Furthermore, these fluorescent spots
correlated with anti-VDAC2 immunoreactivity on a 2D immuno-
blot of wild-type mitochondrial extracts (Figure S3). Second,
we used an affinity approach (Boyce et al., 2011) to confirm
our glyco-DIGE results with VDAC2. We labeled wild-type or
VDAC2/ MEFs with GalNAz, made mitochondrial extracts,
and reacted them with phosphine-biotin to tag azide-bearing
proteins. Then, we enriched for GalNAz-labeled proteins via anti-
biotin affinity chromatography. As expected, anti-VDAC2 immu-
noblotting showed that VDAC2 was affinity purified only from
wild-type mitochondrial samples from cells labeled with GalNAz
(Figure 2C), demonstrating the specificity of GalNAz labeling of
VDAC2. As further confirmation, we analyzed similar biotin affin-
ity-purified samples by mass spectrometry and detected enrich-
ment of VDAC2 in mitochondrial extracts from GalNAz-treated,
but not vehicle-treated, wild-type MEFs (Figure S4). Taken
together, these results indicate that VDAC2 is an O-GlcNAcy-
lated mitochondrial protein in human and mouse cells.
Loss of VDAC2 Protects Cells from Mitochondrial
Dysfunction and Apoptosis following Global
Perturbation of O-GlcNAcylation
Intriguingly, VDAC2 (Cheng et al., 2003; Ren et al., 2009;
Shoshan-Barmatz et al., 2010) and O-GlcNAc (Hu et al., 2009;
Wang and Schwarz, 2009) are both critical regulators of
AB
C
Figure 2. Glyco-DIGE Identifies VDAC2 as a Mitochondrial Glyco-
protein
(A) Jurkat cells were metabolically labeled with 100 mM Ac4GalNAz for 24 hr,
and mitochondrial and cytosolic extracts were prepared. Mitochondrial
extracts were reacted with 1 (green), and cytosolic extracts with 2 (red). Then,
the samples weremixed and analyzed by glyco-DIGE. 1+2 overlap is indicated
in yellow. Arrows point to VDAC2 spots. The characteristic ‘‘charge train’’
pattern of VDAC2 spots likely reflects the presence of multiple phosphorylated
forms of the protein.
(B) Wild-type and VDAC2/ MEFs were metabolically labeled with 100 mM
Ac4GalNAz for 24 hr. Mitochondrial extracts were prepared and labeled with 1
(wild-type is in green) or 2 (VDAC2/ is in red) and then analyzed by glyco-
DIGE. Arrows indicate VDAC2 spots.
(C) Wild-type (WT) and VDAC2/ (ø) MEFs were metabolically labeled with
100 mM Ac4GalNAz or vehicle only for 24 hr, and mitochondrial extracts were
prepared and reacted with phosphine-biotin. Then, biotin-tagged proteins
were affinity purified essentially as described (Boyce et al., 2011) and analyzed
by immunoblot. Left view shows affinity-purified material. Right view presents
3% total input of material (loading control). MnSOD serves as a loading control
for total mitochondrial protein and demonstrates the removal of un-
glycosylated proteins during affinity purification.
See also Figures S1, S2, S3, and S4.
Cmitochondrial metabolism and cell death, but no experimental
evidence had established a functional connection between
them. Given our finding that VDAC2 is a glycoprotein, we asked
whether a phenotypic relationship existed between O-GlcNAc
signaling and VDAC2. We found that potentiating global
O-GlcNAc levels using a combination of glucosamine, to in-
crease levels of UDP-GlcNAc (Vosseller et al., 2002), and Thia-
met-G, a specific small molecule inhibitor of the glycoside
hydrolase O-GlcNAcase (OGA) (Yuzwa et al., 2008), resulted in
mitochondrial dysfunction and apoptosis in MEFs (Figure 3).
Consistent with previous reports by Gloster et al. (2011) and
Slawson et al. (2005), both wild-type and VDAC2/ MEFs
altered OGA and OGT protein levels to compensate for the phar-
macological perturbation of O-GlcNAc, especially at later time
points (Figures 3B and S5). Nevertheless, we found that
VDAC2/MEFs were resistant to the mitochondrial dysfunction
(Figure 3A) and apoptosis (Figure 3B) caused by Thiamet-G and
glucosamine. Furthermore, this difference was caused by the
loss of VDAC2 per se, and not an adventitious or irreversible
downstream effect of gene deletion, because stable re-expres-
sion of VDAC2 in VDAC2/ MEFs restored sensitivity to Thia-
met-G/glucosamine treatment (Figure S6). We concluded that
global O-GlcNAc perturbation induces mitochondrial dysfunc-
tion and apoptosis and that VDAC2 is required for these effects,
demonstrating a critical functional connection between VDAC2
and O-GlcNAc signaling in organelle physiology and cell death.
DISCUSSION
We have developed a proteomics platform, termed glyco-DIGE,
which can detect differences in O-GlcNAcylated proteins across
samples. Importantly, the combination of GalNAz labeling and
glyco-DIGE permits time-resolved examination of new cellular
O-GlcNAc and allows the detection of rare, substoichiometric,
sample-dependent changes in O-GlcNAcylated substrates,
without incurring the bias toward abundant, unchanging,
multiply glycosylated ‘‘background’’ substrates that is endemic
to affinity-based analysis of O-GlcNAc. Therefore, whereasell Reports 5, 546–552, October 31, 2013 ª2013 The Authors 549
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Figure 3. Loss of VDAC2 Protects Cells from Mitochondrial
Dysfunction and Cell Death Induced by Global O-GlcNAc Perturba-
tion
(A) Wild-type or VDAC2/ cells were treated with 10 mMThiamet-G and 4mM
glucosamine or vehicle control for 26 or 50 hr and analyzed by MTS assay to
measure mitochondrially produced reducing equivalents (i.e., NADH and
NADPH). Treated samples were normalized to their corresponding vehicle-
only controls. Error bars represent SDs.
(B) Wild-type or VDAC2/ cells were treated as in (A), and whole-cell lysates
were prepared and analyzed by immunoblot as indicated.
See also Figures S5 and S6.affinity-based approaches will remain valuable for the bulk iden-
tification of O-GlcNAc substrates, we anticipate that GalNAz
labeling and glyco-DIGE will provide an important complemen-
tary method to examine subtle, functionally relevant changes in
O-GlcNAc. In a proof-of-principle experiment, we used glyco-
DIGE to perform an unbiased search for mitochondria-specific
O-GlcNAcylated proteins (Figure 2). We expect that our method
will also lend itself to numerous applications for examining
signal-dependent changes in O-GlcNAc. For example, in prelim-
inary experiments, we used glyco-DIGE to examine differences
in nuclear O-GlcNAcylated proteins in control versus DNA-550 Cell Reports 5, 546–552, October 31, 2013 ª2013 The Authorsdamaged cells and found genotoxic stress-specific changes
conserved across disparate human cell lines (Figure S7). The
identification of these and other signal-specific glyco-DIGE pro-
tein spots is ongoing. More generally, we note that conventional
DIGE methods can resolve 2,500 cyanine-labeled protein
spots from samples of 1,000–10,000 mammalian cells (Meyer
and Stu¨hler, 2007; Minden et al., 2009), and we anticipate that
glyco-DIGE capabilities will be comparable. In addition, glyco-
DIGE experiments can be easily tailored to specific pI and
molecular weight (MW) ranges (narrow or broad, as appropriate)
using commercial reagents, and glyco-DIGE is compatible with a
wide variety of biochemical procedures for sample prefractiona-
tion. Therefore, glyco-DIGE will be useful in analyzing even more
complex biological samples in the future.
In the current work, we used glyco-DIGE to identify VDAC2 as
a mitochondrial O-GlcNAc substrate and showed that the mito-
chondrial dysfunction and cell death caused by global O-GlcNAc
perturbation depend on VDAC2. Interestingly, although VDAC2
has a previously described role in apoptosis, its loss was shown
to sensitize cells to such stimuli as protein kinase inhibition, gen-
otoxic stress (Cheng et al., 2003), and T cell receptor ligation
(Ren et al., 2009), whereas we find that the loss of VDAC2 pro-
tects cells from global O-GlcNAc perturbation. Given the well-
known roles of O-GlcNAc and VDAC2 in apoptotic signaling
and cell metabolism, it will be interesting to dissect themolecular
explanation for VDAC2’s various pro- and antiapoptotic effects
in response to distinct stimuli and determine whether these phe-
notypes are controlled directly by O-GlcNAcylation of VDAC2
itself and/or by other mechanisms. To this end, we are working
to identify the glycosylation site(s) on VDAC2 and will use ungly-
cosylatable mutants to address these questions in future work.
Beyond mitochondrial O-GlcNAc, we believe glyco-DIGE will
serve as a useful tool for analyzing rare, signal-dependent
changes in O-GlcNAcylated proteins, providing a powerful com-
plement to existing affinity-based approaches for studying
O-GlcNAc signaling in a wide range of experimental contexts.
EXPERIMENTAL PROCEDURES
Compound Synthesis and Small Molecule Reagents
Glyco-DIGE probes 1 and 2 were synthesized from propargyl amine and N-
hydroxysuccinamide esters of Cy3 and Cy5, respectively (GE Healthcare),
and purified by reversed-phase high-performance liquid chromatography.
See Extended Experimental Procedures for details. Syntheses and purification
of peracetylated GalNAz (Laughlin and Bertozzi, 2007), phosphine-biotin
(Saxon and Bertozzi, 2000), and Thiamet-G (Yuzwa et al., 2008) were per-
formed essentially as described. Other chemical reagents were obtained
from Sigma-Aldrich unless otherwise indicated.
Cell Culture, Treatment, and Protein Sample Preparation
Cells were maintained in a 5%CO2, humidified atmosphere at 37
C in medium
(Jurkat: RMPI 1640; MEFs, HT1080, 293T: Dulbecco’s modified Eagle’s me-
dium) plus 10% fetal bovine serum and penicillin/streptomycin (Invitrogen). A
total of 100 mM DMSO stock solution of peracetylated GalNAz was added
to achieve final treatment conditions.
For whole-cell lysates, cells were treated as indicated, washed in cold PBS,
and resuspended in Buffer L (1% Triton X-100, 150 mM NaCl, 20 mM Tris-HCl
[pH 7.4]) plus Protease Inhibitor Cocktail III (Calbiochem). Lysates were probe
sonicated (Misonix) on ice for 1 min and cleared by centrifugation.
For subcellular fractionation, mitochondria were prepared as described by
Frezza et al. (2007), and mitochondrial protein extracts were made from
purified organelles as outlined above. For cytosolic protein extracts, superna-
tant from the final spin of the mitochondrial preparation was cleared by high-
speed centrifugation and brought to Buffer L reagent concentrations. Highly
purified nuclear extracts were prepared as described (Boyce et al., 2011).
Where indicated (Figure S1), nuclear/cytoplasmic fractions were prepared
by recombining the nuclear and cytoplasmic material after isolation of mito-
chondria. The quality of subcellular fractionations was verified by immunoblot
for known organelle marker proteins (Figures 2C and S1).
For DNA damage experiments, cells were treated with 100 mM GalNAz and
either 1 mg/ml doxorubicin or vehicle control (DMSO) for 24 hr. Then, nuclear
extracts were made and analyzed pairwise (i.e., with versus without doxoru-
bicin) in glyco-DIGE experiments as described below.
In all cases, protein concentrations were quantified by bicinchoninic acid
assay (Thermo Fisher Scientific), and all samples were normalized with buffer
to the same total protein concentration.Where indicated, equal protein loading
was verified by control immunoblot (e.g., tubulin, MnSOD) or colloidal blue
stain (Invitrogen).
Bioorthogonal Reactions of Azides
For CuAAC reactions, protein extracts were mixed with 25 mM 1 or 2 as indi-
cated, 5 mM sodium ascorbate, 100 mM Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)
methyl]amine (TBTA), and 1 mM CuSO4 (final concentrations) from the
following stock solutions: 10 mM 1 or 2 (in water); 167 mM sodium ascorbate
(in water, prepared fresh); 30 mM TBTA (in DMSO); and 50 mM CuSO4 (in
water). Reactions were incubated in the dark with end-over-end inversion for
1 hr and then stopped by addition of 10 mM (final) EDTA.
For Staudinger ligation reactions, protein extracts were mixed with 500 mM
phosphine-biotin (final concentration, from 5mM stock in 30%dimethylforma-
mide in PBS) and incubated overnight with end-over-end inversion. NeutrAvi-
din antibiotin affinity chromatography was performed as described (Boyce
et al., 2011).
Glyco-DIGE Sample Analysis and Spot Picking
To perform a glyco-DIGE experiment, equal protein amounts of 1- and 2-
labeled samples were combined, and excess, unreacted alkyne probe was
removed by exchange into Buffer L plus 10 mM EDTA using Bio-Spin P-6 col-
umns (Bio-Rad). Labeled protein was precipitated and washed using the 2D
Clean-Up Kit (GE Healthcare) and dissolved in DeStreak Rehydration Solution
(GE Healthcare) with 20 mM dithiothreitol (DTT) and 0.5% IPG Buffer pH 3–10
NL (GE Healthcare).
For the IEF dimension, samples (200 mg to 1 mg of protein) were rehydra-
tion loaded onto 11 cm pH 3–11 NL Immobiline DryStrip IEF strips (GE
Healthcare) using an Ettan IPGphor 3 IEF unit according to the manufac-
turer’s instructions. For the second (i.e., SDS-PAGE) dimension, IEF strips
were equilibrated by incubation in SDS equilibration buffer (6 M urea,
75 mM Tris-HCl [pH 8.8], 29.3% glycerol, 2% SDS, bromophenol blue) with
10 mg/ml DTT for 15 min, followed by incubation in SDS equilibration buffer
with 25 mg/ml iodoacetamide for 15 min. Equilibrated strips were laid over
precast 10% or 4%–20% gradient Criterion IEF SDS-PAGE gels (Bio-Rad)
and sealed into place using 1% agarose and bromophenol blue in 13 MES
buffer (Bio-Rad). Standard SDS-PAGE was then performed using the Crite-
rion gel system (Bio-Rad).
Finished glyco-DIGE gels were washed briefly in ultrapure water and
immobilized by sealing with 1% agarose in water onto a custom-built low-
fluorescence glass stage marked with fluorescent stickers (GE Healthcare).
Immobilized gels were scanned on a Typhoon flatbed gel scanner (GE
Healthcare) using the factory preset excitation and emission settings for
Cy3 and Cy5 and DIGE data acquisition mode. Data were analyzed using
ImageQuant TL software (GE Healthcare). Fluorescent protein spots of
interest were identified by inspection and marked via the ImageQuant 2D
gel analysis tool to make a pick list, using the fluorescent guide stickers as
reference coordinates. Gel coordinates of spots on the pick list were
exported to Excel (Microsoft) and converted to a text file using an in-house
macro. Spots from the pick list were excised from the gel using an Ettan
Spot Picker robot (GE Healthcare) according to the manufacturer’s instruc-
tions into 96-well plates. Gel picks from the same spot were pooled by
hand for proteomic analysis.CImmunoblotting
Immunoblotting was performed essentially as described (Boyce et al., 2011).
See Extended Experimental Procedures for details.
Mass Spectrometric Analysis
Samples were subjected to reversed-phase chromatography with an Agilent
1200 liquid chromatography system connected in-line to either an LTQ XL
mass spectrometer or an LTQ Orbitrap XL hybrid mass spectrometer and pro-
cessed using customized data-dependent acquisition methods. Protein iden-
tities were obtained using the SEQUEST search algorithm within Proteome
Discoverer 1.3 (Thermo Fisher Scientific). See Extended Experimental Proce-
dures for details.
Assay of Mitochondrial Function
Wild-type and VDAC2/MEFs were plated in 96-well plates (5,000 cells/well)
in phenol red-free medium (Invitrogen). Cells were treated as indicated and
analyzed by CellTiter AQueous One Solution Cell Proliferation Assay (to mea-
sure reducing equivalents, NADH and NADPH) or Caspase-Glo 3/7 Assay (to
measure apoptotic protease activity) (Promega) according to the manufac-
turer’s instructions. Results were read using a Molecular Devices SpectraMax
automated plate reader using the appropriate factory preset parameters.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
eight figures and can be found with this article online at http://dx.doi.org/10.
1016/j.celrep.2013.08.048.
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